Jan Drappatz
Jan Drappatz
Associate Professor Neurology
Verified email at
Cited by
Cited by
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
TT Batchelor, AG Sorensen, E di Tomaso, WT Zhang, DG Duda, ...
Cancer cell 11 (1), 83-95, 2007
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence
AD Norden, GS Young, K Setayesh, A Muzikansky, R Klufas, GL Ross, ...
Neurology 70 (10), 779-787, 2008
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ...
The Lancet Oncology 18 (10), 1373-1385, 2017
Phase II study of cediranib, an oral pan–vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
TT Batchelor, DG Duda, E di Tomaso, M Ancukiewicz, SR Plotkin, ...
Journal of Clinical Oncology 28 (17), 2817, 2010
Differential sensitivity of glioma-versus lung cancer–specific EGFR mutations to EGFR kinase inhibitors
I Vivanco, HI Robins, D Rohle, C Campos, C Grommes, PL Nghiemphu, ...
Cancer discovery 2 (5), 458-471, 2012
Antiangiogenic therapies for high-grade glioma
AD Norden, J Drappatz, PY Wen
Nature Reviews Neurology 5 (11), 610-620, 2009
Novel anti-angiogenic therapies for malignant gliomas
AD Norden, J Drappatz, PY Wen
The Lancet Neurology 7 (12), 1152-1160, 2008
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
TJ Kaley, P Wen, D Schiff, K Ligon, S Haidar, S Karimi, AB Lassman, ...
Neuro-oncology 17 (1), 116-121, 2015
Medical management of patients with brain tumors
PY Wen, D Schiff, S Kesari, J Drappatz, DC Gigas, L Doherty
Journal of neuro-oncology 80, 313-332, 2006
Medical therapies for meningiomas
PY Wen, E Quant, J Drappatz, R Beroukhim, AD Norden
Journal of neuro-oncology 99, 365-378, 2010
Atypical and anaplastic meningiomas treated with bevacizumab
L Nayak, FM Iwamoto, JD Rudnick, AD Norden, EQ Lee, J Drappatz, ...
Journal of neuro-oncology 109, 187-193, 2012
Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas
L Doherty, DC Gigas, S Kesari, J Drappatz, R Kim, J Zimmerman, ...
Neurology 67 (1), 156-158, 2006
Phase I study of GRN1005 in recurrent malignant glioma
J Drappatz, A Brenner, ET Wong, A Eichler, D Schiff, MD Groves, ...
Clinical Cancer Research 19 (6), 1567-1576, 2013
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
EC Quant, AD Norden, J Drappatz, A Muzikansky, L Doherty, D LaFrankie, ...
Neuro-oncology 11 (5), 550-555, 2009
Morphological characteristics of brain tumors causing seizures
JW Lee, PY Wen, S Hurwitz, P Black, S Kesari, J Drappatz, AJ Golby, ...
Archives of neurology 67 (3), 336-342, 2010
Phase II study of protracted daily temozolomide for low-grade gliomas in adults
S Kesari, D Schiff, J Drappatz, D LaFrankie, L Doherty, EA Macklin, ...
Clinical Cancer Research 15 (1), 330-337, 2009
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS
FS Hodi, DA Oble, J Drappatz, EF Velazquez, N Ramaiya, ...
Nature clinical practice Oncology 5 (9), 557-561, 2008
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)
PY Wen, WKA Yung, KR Lamborn, AD Norden, TF Cloughesy, LE Abrey, ...
Neuro-oncology 11 (6), 853-860, 2009
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
PY Wen, SM Chang, KR Lamborn, JG Kuhn, AD Norden, TF Cloughesy, ...
Neuro-oncology 16 (4), 567-578, 2014
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
AD Norden, J Drappatz, A Muzikansky, K David, M Gerard, MB McNamara, ...
Journal of Neuro-oncology 92, 149-155, 2009
The system can't perform the operation now. Try again later.
Articles 1–20